MiMedx price target lowered to $12 from $14 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on MiMedx to $12 from $14 and keeps a Buy rating on the shares. The firm notes the quarter was a modest miss, but the revised guide was the bigger surprise, resulting a cut to its numbers. Guidance was lowered to mid to high single-digit revenue growth, from low double digits, as a result of several headwinds, Craig-Hallum adds.